These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3097710)

  • 1. Fluphenazine activity and antipsychotic response.
    Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
    Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
    Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine plasma levels and clinical response.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 9. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
    Dencker SJ; Johansson R; Lundin L; Malm U
    Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
    Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
    Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
    Landmark J; Merskey H; Cernovsky ZZ
    Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluphenazine plasma levels and clinical response.
    Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
    Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.